Tiziana Life Sciences reports continued improvements in second patient with secondary progressive multiple sclerosis after intranasal foralumab treatmentProactive Investors • 09/20/22
Tiziana Life Sciences Announces Continued Clinical Improvements in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) After Six Months of Dosing with Intranasal ForalumabGlobeNewsWire • 09/20/22
Tiziana Life Sciences says Brigham and Women's Hospital gets grant to explore use of intranasal anti-CD3 mAb in ALSProactive Investors • 09/15/22
Tiziana Life Sciences Announces Grant received by the Brigham and Women's Hospital to Explore the Use of Intranasal anti-CD3 mAb in Amyotrophic Lateral SclerosisGlobeNewsWire • 09/15/22
Tiziana Life Sciences says study using nasal anti-CD3 (Foralumab) presented at the Alzheimer's Association International ConferenceProactive Investors • 08/01/22
Tiziana Life Sciences Announces Presentation at Alzheimer's Association International Conference® 2022 (AAIC®) Evaluating Intranasal anti-CD3 for the Potential Treatment of Alzheimer's DiseaseGlobeNewsWire • 08/01/22
Tiziana Life Sciences appoints Dr Matthew Davis as its chief medical officer and acting chief scientific officer, effective immediatelyProactive Investors • 07/18/22
Tiziana Life Sciences Appoints Matthew W. Davis, MD, RPh as Chief Medical Officer and Acting Chief Scientific OfficerGlobeNewsWire • 07/18/22
Tiziana Life Sciences PLC (TLSA: NASDAQ) Releases Research Report: Clinical Improvements for 2nd SPMS PatientGlobeNewsWire • 06/09/22
Tiziana Life Sciences Announces An Interview on Clinical Improvements for 2nd SPMS PatientGlobeNewsWire • 06/09/22
Tiziana Life Sciences PLC (TLSA: NASDAQ) Clinical Improvements for 2nd SPMS PatientGlobeNewsWire • 06/09/22
Tiziana Life Sciences Shares Jump After Multiple Sclerosis Data From Second PatientBenzinga • 06/08/22
Tiziana Life Sciences reports positive results from second patient in multiple sclerosis study of foralumabProactive Investors • 06/08/22
Tiziana Life Sciences Announces Positive Clinical Results in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) Following Three Months of Dosing with Intranasal ForalumabGlobeNewsWire • 06/08/22
Tiziana Life Sciences to Present at the 2022 Biotechnology Innovation Organization Annual Convention to Discuss Recent Updates to Ongoing Clinical ProgramsGlobeNewsWire • 06/06/22
Data from Secondary Progressive Multiple Sclerosis Patient Treated with Intranasal Treatment with Foralumab will be Presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2022 Annual MeetingGlobeNewsWire • 06/01/22
Tiziana Life Sciences Ltd. Announces Annual Report Filed to Regain Nasdaq ComplianceGlobeNewsWire • 05/24/22
Tiziana Life Sciences to participate in a Fireside Chat At the B. Riley Securities 2022 Virtual Neuro & Ophthalmology ConferenceGlobeNewsWire • 04/26/22
Tiziana Life Sciences receives FDA go-ahead to enroll more multiple sclerosis patients in expanded access program for treatment with intranasal foralumabProactive Investors • 04/05/22
FDA Grants Permission to Enroll up to 8 Additional Secondary Progressive Multiple Sclerosis (SPMS) Patients in the Expanded Access Program with Intranasal ForalumabGlobeNewsWire • 04/05/22
Tiziana Announces Initiation of Phase 1b Clinical Trial in Crohn's Disease Patients to Evaluate Oral Capsules of Foralumab, a Fully Human Anti-CD3 Monoclonal AntibodyGlobeNewsWire • 03/25/22
Tiziana Life Sciences: Analyst shares his feedback from key opinion leader call on ForalumabProactive Investors • 03/15/22
Tiziana Life Sciences Hosting Key Opinion Leader Virtual Event to Discuss the Intranasal Delivery of Foralumab in Multiple SclerosisGlobeNewsWire • 03/11/22